SMALL CELL LUNG CANCER ( SCLC )

This early-phase study tests a new radioactive drug, 225Ac-ABD147, in people with small cell lung cancer or large cell neuroendocrine lung cancer that has spread and was previously treated with platinum chemotherapy. The main goals are to check safety, find the best dose, and see…

This phase 2 trial is testing tarlatamab, an experimental drug given by IV, in 252 adults with small cell lung cancer that has worsened after platinum-based chemotherapy. The main goal is to see if the drug can shrink tumors (partial or complete response). Researchers will also m…

This phase 3 study compares tarlatamab, an experimental drug, to standard treatments in about 500 adults with small cell lung cancer that returned after initial chemotherapy. The main goal is to see if tarlatamab helps people live longer. Participants must have measurable disease…

This phase 2 trial tests the immunotherapy drug pembrolizumab (Keytruda) in people with 15 types of advanced solid tumors that have worsened after standard treatments. About 1,600 participants receive the drug to see if their tumors shrink or stop growing. The study also looks fo…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study follows 160 lung cancer patients to see if their muscle mass, strength, and function are linked to how well they tolerate treatment and their overall survival. Researchers will also explore why some patients struggle to complete their therapy. The goal is to find ways …